The trading price of Pacific Biosciences of California Inc (NASDAQ:PACB) closed higher on Monday, April 22, closing at $1.56, 0.65% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $14.55 and a 52-week low of $1.25. Over the past month, the stock has lost -59.38% in value.
Pacific Biosciences of California Inc, whose market valuation is $424.76 million at the time of this writing, is expected to release its quarterly earnings report Apr 30, 2024 – May 06, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Pacific Biosciences of California Inc No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest PACB has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
A quick review shows that PACB’s price is currently -48.82% off the SMA20 and -63.09% off the SMA50. The RSI metric on the 14-day chart is currently showing 20.83, and weekly volatility stands at 22.32%. When measured over the past 30 days, the indicator reaches 11.06%. Pacific Biosciences of California Inc (NASDAQ:PACB)’s beta value is currently sitting at 2.02, while the Average True Range indicator is currently displaying 0.35.
To see how Pacific Biosciences of California Inc stock has been performing in comparison to its peers in the industry, here are the numbers: PACB stock’s performance was 0.65% in the latest trading, and -85.81% in the past year.
An evaluation of the daily trading volume of Pacific Biosciences of California Inc (NASDAQ:PACB) indicates that the 3-month average is 9.74 million.
Currently, records show that 267.74 million of the company’s shares remain outstanding. The insiders hold 6.08% of outstanding shares, whereas institutions hold 101.19%. However, since the stock’s price has seen -84.10% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
